newsfilter
← Latest News
Business Wire·

Pear Therapeutics Reports Third Quarter 2022 Results

Grew revenue 24% quarter-over-quarter to $4.1 million Expanded patient access with new state and commercial payors Expanded real-world evidence with new peer reviewed publication Reduced quarter-over-quarter